CD274 and neoplasm: Despite being imperfect, PD-L1 expression levels in tumor cells, as reflected by Immunohistochemical (IHC) staining, are predictive biomarkers for clinical effects in anti-PD-1 and anti-PD-L1 therapies15,16.